Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute for Neurodegenerative Disorders
• Collaborators: GE Healthcare; Pfizer
• Treatments: Cabergoline; Carbidopa; Carbidopa, levodopa drug combination; Dopamine; Levodopa

Criteria

Inclusion Criteria:

• The subject is aged 40 years or older.

• Written informed consent is obtained.

• Subjects have a clinical diagnosis of idiopathic Parkinson's disease.

• Hoehn and Yahr stages for subjects are I-II.

Exclusion Criteria:

• The subject has atypical or drug-induced Parkinson's disease.

• The subject has dementia.

• The subject has clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.

• The subject is pregnant.